Merck to buy N.H. biotech in record bid
Privately held GlycoFi to net $400m in cash
A small New Hampshire firm with a new idea for making biotechnology drugs said yesterday it would be acquired by global pharmaceutical giant Merck & Co. for $400 million in cash, the largest such deal ever reported for a private biotechnology company. (Full article: 469 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
